S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Sell every Stock except ONE (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Sell every Stock except ONE (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Sell every Stock except ONE (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Sell every Stock except ONE (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Sell every Stock except ONE (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Sell every Stock except ONE (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Sell every Stock except ONE (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Sell every Stock except ONE (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NASDAQ:CDNA

CareDx - CDNA Stock Forecast, Price & News

$17.02
-0.08 (-0.47%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$16.96
$17.77
50-Day Range
$16.06
$26.39
52-Week Range
$15.66
$75.92
Volume
745,819 shs
Average Volume
865,644 shs
Market Capitalization
$909.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.50

CareDx MarketRank™ Forecast

Analyst Rating
Buy
3.33 Rating Score
Upside/​Downside
232.0% Upside
$56.50 Price Target
Short Interest
Bearish
7.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.65mentions of CareDx in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$62,546 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.54) to ($1.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

634th out of 1,095 stocks

Medical Laboratories Industry

17th out of 30 stocks

CDNA stock logo

About CareDx (NASDAQ:CDNA) Stock

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

CDNA Stock News Headlines

CareDx, Inc. (NASDAQ: CDNA)
CareDx (NASDAQ:CDNA) Sees Unusually-High Trading Volume
Form 8-K CareDx, Inc. For: Sep 07 - StreetInsider.com
See More Headlines
Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

CDNA Company Calendar

Last Earnings
8/04/2022
Today
10/02/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDNA
Employees
633
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$56.50
High Stock Price Forecast
$87.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+232.0%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$-30,660,000.00
Pretax Margin
-22.40%

Debt

Sales & Book Value

Annual Sales
$296.40 million
Book Value
$8.82 per share

Miscellaneous

Free Float
50,999,000
Market Cap
$909.89 million
Optionable
Optionable
Beta
1.02

Key Executives

  • Dr. Reginald  SeetoDr. Reginald Seeto (Age 50)
    Pres, CEO & Director
    Comp: $1.51M
  • Ms. Sasha  King M.B.A.Ms. Sasha King M.B.A. (Age 36)
    Chief Marketing Officer & Franchise Head of Kidney Transplant
    Comp: $628.87k
  • Dr. Peter Maag Ph.D. (Age 55)
    Exec. Director
    Comp: $791.45k
  • Mr. Marcel Konrad (Age 46)
    Sr. VP of Fin. & Accounting
    Comp: $167.96k
  • Mr. Alexander L. Johnson (Age 47)
    Chief Bus. Officer & Head of Testing Services
    Comp: $716.54k
  • Mr. Ankur  DhingraMr. Ankur Dhingra (Age 46)
    Consultant
    Comp: $909.26k
  • Mr. Abhishek Jain (Age 46)
    Interim CFO, VP, Corp. Controller, Principal Financial Officer & Principal Accounting Officer
  • Mr. Ian Cooney
    VP of Investor Relations
  • Mr. Abraham Ronai Esq.
    Gen. Counsel
  • Dr. Mickey Y. Kim M.D.
    Sr. VP of Corp. Devel. & Strategy













CDNA Stock - Frequently Asked Questions

Should I buy or sell CareDx stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CDNA shares.
View CDNA analyst ratings
or view top-rated stocks.

What is CareDx's stock price forecast for 2022?

3 analysts have issued 12 month price objectives for CareDx's shares. Their CDNA share price forecasts range from $37.00 to $87.00. On average, they anticipate the company's share price to reach $56.50 in the next year. This suggests a possible upside of 232.0% from the stock's current price.
View analysts price targets for CDNA
or view top-rated stocks among Wall Street analysts.

How have CDNA shares performed in 2022?

CareDx's stock was trading at $45.48 at the beginning of the year. Since then, CDNA stock has decreased by 62.6% and is now trading at $17.02.
View the best growth stocks for 2022 here
.

When is CareDx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our CDNA earnings forecast
.

How were CareDx's earnings last quarter?

CareDx, Inc (NASDAQ:CDNA) issued its quarterly earnings data on Thursday, August, 4th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.11. The firm earned $80.63 million during the quarter, compared to analysts' expectations of $81.85 million. CareDx had a negative trailing twelve-month return on equity of 15.09% and a negative net margin of 22.04%. The firm's revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.04) earnings per share.

What guidance has CareDx issued on next quarter's earnings?

CareDx issued an update on its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $325.00 million-$335.00 million, compared to the consensus revenue estimate of $337.92 million.

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

How do I buy shares of CareDx?

Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $17.02.

How much money does CareDx make?

CareDx (NASDAQ:CDNA) has a market capitalization of $909.89 million and generates $296.40 million in revenue each year. The company earns $-30,660,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

How many employees does CareDx have?

The company employs 633 workers across the globe.

How can I contact CareDx?

CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.caredxinc.com. The company can be reached via phone at (415) 287-2300, via email at caroline.corner@westwicke.com, or via fax at 415-287-2450.

This page (NASDAQ:CDNA) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.